Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow NVO by emailGet an email when NVO pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NVO, unsubscribe in one click. Privacy
📣 What NVO Says Is Next
Q4 2026 · “The 25 mg dose for Ozempic ® pill was submitted for US FDA approval earlier in the year with an expected FDA decision during Q4 2026.”
Company press release, Aug 4, 2026 · SEC filing
second half of 2026 · “The recommendation also includes data from SELECT which demonstrates that Wegovy® reduces the risk of major adverse cardiovascular events (MACE)*, in the label. · Wegovy® pill is the only oral GLP-1 treatment with no drug-drug restrictions in the label. · Novo Nordisk plans to launch Wegovy® pill in select markets outside the US in the second half of 2026.”
Company press release, May 22, 2026 · SEC filing
second half of 2026 · “For Wegovy ® pill, pending regulatory decisions, Novo Nordisk expects to launch in the first markets outside the US during the second half of 2026.”
Company press release, May 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full NVO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NVO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.